Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nizar Tannir

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|January 4, 2018
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapyNizar Tannir, Hans Hammers, Asim Amin
Current Clinical Pharmacology|August 11, 2011
Adjuvant and neoadjuvant therapy in renal cell carcinomaMichel Choueiri, Nizar Tannir, Eric Jonasch
Medical Oncology (Northwood, London, England)|January 1, 2010
Experience with sorafenib and the elderly patientJanice P Dutcher, Nizar Tannir, Joaquim Bellmunt, et al.
Expert Review of Anticancer Therapy|June 29, 2011
Systemic therapy for sarcomatoid renal cell carcinomaLance C Pagliaro, Nizar Tannir, Kanishka Sircar, et al.
Cancer|April 13, 2011
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinomaJonathan Verma, Eric Jonasch, Pamela Allen, et al.
Cancer|February 26, 2009
Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measuresElizabeth R Plimack, Nizar Tannir, E Lin, et al.
Cancer|April 7, 2006
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanesAlan Rodney, Pauline Dieringer, Paul Mathew, et al.
Journal of Behavioral Medicine|June 18, 2014
Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinomaSarah Prinsloo, Qi Wei, Shellie M Scott, et al.
The Journal of Urology|May 20, 2008
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinomaVitaly Margulis, Surena F Matin, Nizar Tannir, et al.
American Journal of Clinical Oncology|August 16, 2012
The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinomaJonathan Verma, Eric Jonasch, Pamela K Allen, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|January 4, 2018
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapyNizar Tannir, Hans Hammers, Asim Amin
Current Clinical Pharmacology|August 11, 2011
Adjuvant and neoadjuvant therapy in renal cell carcinomaMichel Choueiri, Nizar Tannir, Eric Jonasch
Medical Oncology (Northwood, London, England)|January 1, 2010
Experience with sorafenib and the elderly patientJanice P Dutcher, Nizar Tannir, Joaquim Bellmunt, et al.
Expert Review of Anticancer Therapy|June 29, 2011
Systemic therapy for sarcomatoid renal cell carcinomaLance C Pagliaro, Nizar Tannir, Kanishka Sircar, et al.
Cancer|April 13, 2011
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinomaJonathan Verma, Eric Jonasch, Pamela Allen, et al.
Cancer|February 26, 2009
Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measuresElizabeth R Plimack, Nizar Tannir, E Lin, et al.
Cancer|April 7, 2006
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanesAlan Rodney, Pauline Dieringer, Paul Mathew, et al.
Journal of Behavioral Medicine|June 18, 2014
Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinomaSarah Prinsloo, Qi Wei, Shellie M Scott, et al.
The Journal of Urology|May 20, 2008
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinomaVitaly Margulis, Surena F Matin, Nizar Tannir, et al.
American Journal of Clinical Oncology|August 16, 2012
The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinomaJonathan Verma, Eric Jonasch, Pamela K Allen, et al.
Pageof 5